Expert Outlook: ResMed Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
ResMed (NYSE:RMD) has received varied analyst ratings over the past three months, with a recent average price target of $227.57, up 3.68% from the previous target. Analysts' ratings range from 'Outperform' to 'Underperform', reflecting diverse expectations for ResMed's market performance. The company, a leader in respiratory care devices, has shown strong financial health with a 9.01% revenue growth rate and a net margin of 23.89%.
September 24, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed has received a range of analyst ratings, with a new average price target of $227.57, indicating a positive shift. The company's strong financials, including a 9.01% revenue growth rate and a 23.89% net margin, support a favorable outlook.
The increase in the average price target by 3.68% suggests a positive sentiment among analysts. ResMed's strong financial metrics, such as high net margin and revenue growth, further support a likely positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100